Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115477) titled 'Clinical study and mechanism of spleen-strengthening traditional Chinese medicine WD-3 combined with immunotherapy for lung cancer based on the theory of "Pei Tu Shengjin"' on Dec. 26, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Wuxi Hospital of Traditional Chinese Medicine
Condition:
lung cancer
Intervention:
Experimental group:PD-1/PD-L1 inhibitors + chemotherapy + WD-3 mixture granules
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2024-06-03
Target Sample Size: Experimental group:110;Control group:110;
Countries of Recruitment:
China
To ...